Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 16/20 | 0.44 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6417182 | 1.00 | PDE10A (0.44) | PDE10AAPOBEC3ACTDSP1APOBEC3GKDM4E | |
| SCHEMBL259227 | 0.82 | PDE10A (0.43) | PDE10AKDM4ENPC1RAB9A | |
| SCHEMBL259226 | 0.82 | PDE10A (0.43) | PDE10AKDM4ENPC1RAB9A | |
| SCHEMBL260224 | 0.79 | PDE10A (0.50) | PDE10AKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL260223 | 0.79 | PDE10A (0.50) | PDE10AKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL258857 | 0.78 | PDE10A (0.48) | PDE10AKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL258858 | 0.78 | PDE10A (0.48) | PDE10AKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL259831 | 0.77 | PDE10A (0.57) | PDE10A | |
| SCHEMBL259832 | 0.77 | PDE10A (0.57) | PDE10A | |
| SCHEMBL15384521 | 0.75 | PDE10A (0.61) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2637704-B9 | RADIOLABELLED PHENYLIMIDAZOLE-BASED LIGANDS | LUNDBECK & CO AS H (DK) | 2015-08-05 | — | — | EP | disclosed |
| EP-2637704-B1 | RADIOLABELLED PHENYLIMIDAZOLE-BASED LIGANDS | LUNDBECK & CO AS H (DK) | 2015-03-25 | — | — | EP | disclosed |
| US-8592449-B1 | Radiolabelled phenylimidazole-based ligands | H. LUNDBECK A/S (DK) | 2013-11-26 | — | — | US | disclosed |
| US-20130303770-A1 | RADIOLABELLED PHENYLIMIDAZOLE-BASED LIGANDS | H. LUNDBECK A/S (DK) | 2013-11-14 | — | — | US | disclosed |
| US-20130303770-A1 | RADIOLABELLED PHENYLIMIDAZOLE-BASED LIGANDS | H. LUNDBECK A/S (DK) | 2013-11-14 | — | — | US | disclosed |
| EP-2637704-A1 | RADIOLABELLED PHENYLIMIDAZOLE-BASED LIGANDS | H. Lundbeck A/S (DK) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062319-A1 | RADIOLABELLED PHENYLIMIDAZOLE-BASED LIGANDS | H. LUNDBECK A/S (DK) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303770-A1 | RADIOLABELLED PHENYLIMIDAZOLE-BASED LIGANDS | PDE12, PDE5A, PDE3A | PDE10A 6/4885APOBEC3A 1174/4885CTDSP1 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.